The Roche Group posted strong sales growth in the first three months in both divisions, with demand for oncology and immunology medicines driving growth in Pharmaceuticals, and immunodiagnostics products driving growth in Diagnostics.

Novo Nordisk today announced that Saxenda® (liraglutide 3 mg) is now available in the United States (US). Saxenda® is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada.

GSK is further strengthening and expanding its vaccines presence in the US by establishing a new global centre for vaccines research and development (R&D) in Rockville, Maryland. The site will become one of three global vaccines R&D centres for GSK, complementing the company's existing global R&D centres in Rixensart, Belgium and in Siena, Italy, a site which GSK recently acquired from Novartis in March 2015.

Results from a new global survey of lung cancer oncologists have shown that despite 81% of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for EGFR mutations, a significant number of those tested were not receiving personalized treatments for their cancer type and mutation subtype.

Eli Lilly and Company (NYSE:LLY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have agreed to transfer rights to Erbitux® (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Bristol-Myers Squibb to Lilly.

In a major step forward to make patient-centric evidence a cornerstone of scientific discovery and development, AstraZeneca and PatientsLikeMe have signed a five-year agreement to provide access to PatientsLikeMe’s global network in support of AstraZeneca's patient-driven research initiatives.

Today, Novo Nordisk opens a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill® cartridges and FlexPen® prefilled insulin injection pens for the Russian market.